Univariable analyses of LFS after UCBT for childhood AML
. | Two-year Kaplan-Meier estimate of LFS, %* . | P, log-rank test . |
|---|---|---|
| Overall | 42 ± 5 | |
| Diagnosis, de novo vs secondary AML | 40 ± 6 vs 56 ± 16 | .54 |
| WBC count at diagnosis, less than or equal to 50 × 109/L vs greater than 50 × 109/L | 43 ± 7 vs 41 ± 10 | .67 |
| Cytogenetics, “poor-risk” karyotype vs others | 44 ± 11 vs 40 ± 8 | .62 |
| Age at UCBT, younger than 6 y vs 6 y or older | 44 ± 7 vs 39 ± 6 | .67 |
| Recipient's sex, male vs female | 48 ± 7 vs 36 ± 7 | .35 |
| Recipient's weight at UCBT, less than 21 kg vs 21 kg or more | 42 ± 6 vs 42 ± 7 | .96 |
| Recipient's CMV serology prior to UCBT, negative vs positive | 37 ± 7 vs 48 ± 7 | .09 |
| Status at UCBT | .002† | |
| CR1 | 59 ± 11 | |
| CR2 | 50 ± 8 | |
| Subsequent CR | 0 | |
| No CR | 21 ± 9 | |
| Previous transplantation, no vs yes | 38 ± 6 vs 54 ± 11 | .10 |
| Graft/recipient HLA compatibility (high-resolution typing) | .22 | |
| HLA identical | 19 ± 15 | |
| 1 HLA disparity | 45 ± 8 | |
| 2 HLA disparities | 37 ± 9 | |
| 3 or more HLA disparities | 56 ± 17 | |
| ABO compatibility, matched vs minor vs major mismatched | 51 ± 8 vs 42 ± 12 vs 28 ± 9 | .05 |
| Collected nucleated cell dose, less than 5.2 × 107/kg vs 5.2 × 107/kg or more | 38 ± 7 vs 46 ± 8 | .46 |
| Infused nucleated cell dose, less than 4.4 × 107/kg vs 4.4 × 107/kg or more | 36 ± 7 vs 50 ± 8 | .25 |
| Infused CD34+ cell dose, less than 1.38 × 105/kg vs 1.38 × 105/kg or more | 34 ± 9 vs 52 ± 10 | .35 |
| UCBT date, before January 1998 vs after January 1998 | 30 ± 9 vs 46 ± 6 | .04 |
| Conditioning regimen, Bu-containing vs TBI-containing | 33 ± 7 vs 53 ± 8 | .10 |
| Posttransplantation growth factor, no vs yes | 35 ± 8 vs 48 ± 7 | .23 |
| Use of MTX for GVHD prophylaxis, no vs yes | 41 ± 7 vs 41 ± 10 | .67 |
. | Two-year Kaplan-Meier estimate of LFS, %* . | P, log-rank test . |
|---|---|---|
| Overall | 42 ± 5 | |
| Diagnosis, de novo vs secondary AML | 40 ± 6 vs 56 ± 16 | .54 |
| WBC count at diagnosis, less than or equal to 50 × 109/L vs greater than 50 × 109/L | 43 ± 7 vs 41 ± 10 | .67 |
| Cytogenetics, “poor-risk” karyotype vs others | 44 ± 11 vs 40 ± 8 | .62 |
| Age at UCBT, younger than 6 y vs 6 y or older | 44 ± 7 vs 39 ± 6 | .67 |
| Recipient's sex, male vs female | 48 ± 7 vs 36 ± 7 | .35 |
| Recipient's weight at UCBT, less than 21 kg vs 21 kg or more | 42 ± 6 vs 42 ± 7 | .96 |
| Recipient's CMV serology prior to UCBT, negative vs positive | 37 ± 7 vs 48 ± 7 | .09 |
| Status at UCBT | .002† | |
| CR1 | 59 ± 11 | |
| CR2 | 50 ± 8 | |
| Subsequent CR | 0 | |
| No CR | 21 ± 9 | |
| Previous transplantation, no vs yes | 38 ± 6 vs 54 ± 11 | .10 |
| Graft/recipient HLA compatibility (high-resolution typing) | .22 | |
| HLA identical | 19 ± 15 | |
| 1 HLA disparity | 45 ± 8 | |
| 2 HLA disparities | 37 ± 9 | |
| 3 or more HLA disparities | 56 ± 17 | |
| ABO compatibility, matched vs minor vs major mismatched | 51 ± 8 vs 42 ± 12 vs 28 ± 9 | .05 |
| Collected nucleated cell dose, less than 5.2 × 107/kg vs 5.2 × 107/kg or more | 38 ± 7 vs 46 ± 8 | .46 |
| Infused nucleated cell dose, less than 4.4 × 107/kg vs 4.4 × 107/kg or more | 36 ± 7 vs 50 ± 8 | .25 |
| Infused CD34+ cell dose, less than 1.38 × 105/kg vs 1.38 × 105/kg or more | 34 ± 9 vs 52 ± 10 | .35 |
| UCBT date, before January 1998 vs after January 1998 | 30 ± 9 vs 46 ± 6 | .04 |
| Conditioning regimen, Bu-containing vs TBI-containing | 33 ± 7 vs 53 ± 8 | .10 |
| Posttransplantation growth factor, no vs yes | 35 ± 8 vs 48 ± 7 | .23 |
| Use of MTX for GVHD prophylaxis, no vs yes | 41 ± 7 vs 41 ± 10 | .67 |
WBC indicates white blood cell; CMV, cytomegalovirus; TBI, total body irradiation; Bu, Busulfan; and MTX, methotrexate.
Values given as percentage ± SD.